Seattle Genetics (SGEN) - FREE Research Report

Baker Felix who is Director at Seattle Genetics bought 1.0 million shares at $43.19 on Dec. 5, 2013. Following this transaction, the Director owned 351,151 shares meaning that the stake was reduced by 153.63% with the 1.0 million-share transaction.

The shares most recently traded at $43.61, up $0.42, or 0.97% since the insider transaction. Historical insider transactions for Seattle Genetics go as follows:

  • 12-Week # shares sold: 2,000
  • 24-Week # shares sold: 102,000

The average volume for Seattle Genetics has been 835,200 shares per day over the past 30 days. Seattle Genetics has a market cap of $5.4 billion and is part of the health care sector and drugs industry. Shares are up 91.07% year-to-date as of the close of trading on Thursday.

Seattle Genetics, Inc., a biotechnology company, focuses on the development and commercialization of monoclonal antibody-based therapies for cancer. Its product candidate, ADCETRIS, has accelerated approval form the U.S. Currently there are 3 analysts that rate Seattle Genetics a buy, 2 analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SGEN - FREE

TheStreet Quant Ratings rates Seattle Genetics as a sell. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income and feeble growth in its earnings per share. Get the full Seattle Genetics Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Data for this article provided by Zacks Investment Research

If you liked this article you might like

A Robot Will Be Taking Your Job Soon

This Is Why Tech Stocks Are Heading Into the Weekend With a Nasty Hangover

This Pattern on CenturyLink Has My Attention

Warren Buffett Investing in Sprint Would Be Unusual, but Not Unprecedented